Clinical study of the median effective dose (ED50) of esketamine combined with propofol for pediatric in painless gastroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052830

Enrollment

Unknown

Registered

2021-11-06

Start date

2021-11-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy of children

Interventions

1-14 year old children :esketamine combined with propofol

Eligibility

Sex/Gender

All

Age

4 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1.Pediatric patients enrolled in this study aged 1-14 years 2. BMI 18-25 kg/m2 3. American Society of Anesthesiologists (ASA) physical status I -? 4.Normal development.

Exclusion criteria

Exclusion criteria: (1) allergy to esketamine or propofol; (2) definite difficult airway; (3) ongoing sedative therapy (e.g., propofol, morphine, fentanyl, sufentanil, midazolam, dexmedetomidine, ketamine) or recent use of sedatives (withdrawal time < 24 h); (4) cardiac or respiratory system diseases; (5) hepatic or renal malfunction; (6) developmental malformations.

Design outcomes

Primary

Measure	Time frame
Esketamine dosage;	—

Countries

China

Contacts

Public ContactZhang Quanyi

Affiliated Hospital of Binzhou Medical University

Zhang_quan_yi@126.com+86 189 5434 6736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026